Altium Capital Management’s Exagen XGN Stock Holding History

Altium Capital Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-86,475	Closed	-$1.51M	–	158
2021 Q1	$1.51M	Buy	+86,475	New	+$1.54M	0.42%	91

Other funds holding XGN

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Altium Capital Management's XGN Position: Q2 2021 in Review

Altium Capital Management sold out of Exagen (XGN) in Q2 2021, closing a stake of 86,475 shares — an estimated $1.51M sold.

Altium Capital Management first reported a position in XGN in Q1 2021 and held it in 1 quarter. The position peaked at $1.51M in Q1 2021. 54 funds tracked by Wall St. Rank hold XGN as of Q2 2021.

Altium Capital Management reported no remaining Exagen position as of Q2 2021 after selling out during the quarter.
Altium Capital Management sold 86,475 Exagen shares in Q2 2021, an estimated $1.51M.
Altium Capital Management first reported a position in Exagen in Q1 2021 and held it in 1 quarter.
Altium Capital Management's Exagen position peaked at $1.51M in Q1 2021.
54 funds tracked by Wall St. Rank held Exagen as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.